Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.6100 (-2.43%) ($5.4800 - $5.7900) on Fri. Feb. 14, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.3% (three month average) | RSI | 61 | Latest Price | $5.6100(-2.43%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 0.4% a day on average for past five trading days. | Weekly Trend | ADMS advances 4.4% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) IGOV(21%) TBT(12%) UUP(8%) KWEB(5%) BOTZ(4%) | Factors Impacting ADMS price | ADMS will decline at least -3.65% in a week (0% probabilities). PCY(-22%) BWX(-21%) BNDX(-18%) EMHY(-17%) BND(-16%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.65% (StdDev 7.3%) | Hourly BBV | 0 () | Intraday Trend | -1.8% | | | |
|
5 Day Moving Average | $5.69(-1.41%) | 10 Day Moving Average | $5.61(0%) | 20 Day Moving Average | $5.56(0.9%) | To recent high | -23.2% | To recent low | 10% | Market Cap | $159m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |